Joint Clinical Trials Office
FMT and Other Gut Microbial Therapies National Registry: Acute Severe and Fulminant C. Difficile Infection
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2026
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged AML
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2026
The underappreciated role of atherosclerotic cardiovascular disease in primary biliary cholangitis
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 16, 2026
A Phase III, Multisite, Double-Blinded Randomized Trial of BNT327 In Combination with Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab In Combination with Chemotherapy In Participants with First-Line Extensive-Stage Small-Cell Lung Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2026
A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 16, 2026
Repository of Novel Analytes Leading to Autoimmune, Inflammatory, and Diabetic Nephropathies (RENAL AID)
Study Status:
Open to Enrollment
Primary Investigator:
Alan Perlman, M.D.
Date: March 15, 2016
(CLONEVO): Cell cycLe inhbitiON to target the EVolution of urOthelial cancer
Study Status:
Open to Enrollment
Primary Investigator:
Bishoy Faltas, M.D.
Date: June 8, 2018
Autosomal Dominant Polycystic Kidney Disease Data Repository
Study Status:
Open to Enrollment
Primary Investigator:
Blumenfeld, Jon M.D.
Date: April 28, 2016
Fecal Microbiota Transplantation National Registry
Study Status:
Open to Enrollment
Primary Investigator:
Carl V. Crawford, Jr., MD
Date: August 24, 2018
A Gene-Transfer, Open-Label, Dose-Escalation Study of SPK-8011 [Recombinant Adeno-Associated Viral Vector with B-Domain Deleted Human Factor VIII Gene] in Individuals with Hemophilia A
Study Status:
Open to Enrollment
Primary Investigator:
Catherine McGuinn
Date: November 2, 2018